Michael Krams
About Michael Krams
Michael Krams serves as the Chief Quantitative Medicine Officer at Exscientia in Vienna, Austria, a position he has held since 2022. He has extensive experience in the pharmaceutical industry, having previously worked in leadership roles at Johnson & Johnson, Pfizer, and Wyeth.
Work at Exscientia
Michael Krams serves as the Chief Quantitative Medicine Officer at Exscientia, a position he has held since 2022. He operates from the company's office in Vienna, Austria. In this role, he focuses on integrating quantitative methods into the drug discovery process, leveraging data to enhance decision-making and improve outcomes in clinical development.
Previous Experience in Pharmaceutical Industry
Before joining Exscientia, Michael Krams held several significant positions in the pharmaceutical industry. He was the VP and Head of the Neurology Franchise at Johnson & Johnson from 2010 to 2013. Prior to that, he worked at Pfizer as a Senior Director for nine years, from 1997 to 2006. Additionally, he served as the Global Head of Quantitative Sciences at The Janssen Pharmaceutical Companies of Johnson & Johnson from 2013 to 2022, and as VP of Adaptive Trials and Applied Program Strategies at Wyeth from 2006 to 2010.
Education and Expertise
Michael Krams completed his secondary education at Goethe-Gymnasium in Frankfurt/Main, where he achieved the International Baccalaureate from 1972 to 1979. He furthered his education at Ludwig-Maximilians-Universität München, earning a Doctor of Medicine (M.D.) degree from 1982 to 1988. His educational background provides a strong foundation for his expertise in quantitative medicine and clinical development.
Career Timeline
Michael Krams has a diverse career spanning several decades in the pharmaceutical industry. His career began at Pfizer, where he worked as a Senior Director from 1997 to 2006. He then transitioned to Wyeth, serving as VP of Adaptive Trials and Applied Program Strategies from 2006 to 2010. Following this, he joined Johnson & Johnson, where he held various leadership roles, including Global Head of Quantitative Sciences from 2013 to 2022, and VP - Head of Neurology Franchise from 2010 to 2013.